A guide to immunotherapy for COVID-19

FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …

Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review

I Monsef, C Doree, EM Wood… - Cochrane Database …, 2020 - cochranelibrary.com
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

Convalescent plasma for covid-19–induced ARDS in mechanically ventilated patients

B Misset, M Piagnerelli, E Hoste… - … England Journal of …, 2023 - Mass Medical Soc
Background Passive immunization with plasma collected from convalescent patients has
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are …

[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023

World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

P Bégin, J Callum, E Jamula, R Cook, NM Heddle… - Nature medicine, 2021 - nature.com
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …

Early outpatient treatment for Covid-19 with convalescent plasma

DJ Sullivan, KA Gebo, S Shoham… - … England Journal of …, 2022 - Mass Medical Soc
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …

[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …

Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2020 - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

[HTML][HTML] Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

JD Chalmers, ML Crichton… - European respiratory …, 2021 - Eur Respiratory Soc
Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …

A neutralizing monoclonal antibody for hospitalized patients with Covid-19

Activ-3/Tico Ly-CoV555 Study … - New England Journal of …, 2021 - Mass Medical Soc
Background LY-CoV555, a neutralizing monoclonal antibody, has been associated with a
decrease in viral load and the frequency of hospitalizations or emergency department visits …